Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia

August 21, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.

Rheumatic heart disease (RHD) has been practically eradicated in wealthy nations, but in the developing world the disease remains a major cause of morbidity and mortality, particularly in children …

/by

Sandoz receives first aproval in Latin America for innovative respiratory inhaler Airflusal® Forspiro®

  • Mexico’s Health Authority (COFEPRIS) grants marketing authorization for Airflusal® Forspiro®
  • Approval for 50-100mg, 50-250mg and 50-500mg dosage forms
  • Product to be branded IrFlosolTM Forspiro® in Mexico
  • Airflusal® Forspiro® already launched in four European countries as well as in South Korea

Holzkirchen, August 20, 2014 – Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic …

/by

Sandoz Germany launches innovative new topical therapy for erectile dysfunction, a leading urological disorder

  • Sandoz Germany launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)
  • First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability
  • Launch in Sandoz’s largest EU market further demonstrates company commitment to meeting unmet medical need across key therapeutic areas

Holzkirchen, August 18, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros®, an innovative new …

/by

Sandoz Sweden launches innovative new topical therapy for erectile dysfunction,a leading urological disorder

  • Sandoz Sweden launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)
  • First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability
  • Launch demonstrates Sandoz commitment to meeting unmet medical need across key therapeutic areas, including Women’s and Men’s Health

Holzkirchen, August 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Sweden of Vitaros®, an innovative new topical …

/by

FDA accepts Sandoz application biosimilar filgrastim

  • Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA)
  • FDA’s acceptance of Sandoz’s filing is an important first step in increasing US patient access to affordable, high-quality biologics
  • Sandoz is a global leader in biosimilars with over 50% share of the global biosimilars market1

Holzkirchen, July 24, 2014 – Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has …

/by

Sandoz obtains rights in US to commercialize Kerydintm (Tavaborole) topical solution, 5% from Anacor Pharmaceuticals, INC.

Princeton, New Jersey, July 21, 2014 – Sandoz today announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize Anacor’s drug KERYDINTM (tavaborole) topical solution, 5% in the US, through its branded dermatology business, PharmaDerm.

Two weeks ago Anacor announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for KERYDINTM, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes, a fungal …

/by

Sandoz launches authorized generic version of Tobi®

Princeton, New Jersey, July 14, 2014 – Sandoz today announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation1.

Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa.

Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 …

/by

Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook

Basel, July 17, 2014 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis delivered solid financial performance with core margin expansion in the second quarter and first half. Pharmaceuticals, in particular, showed improved productivity, driving core operating leverage for the Group. We also made significant progress on innovation across the portfolio, reaching milestones such as FDA approval for Zykadia in ALK+ non-small cell lung cancer, FDA Fast Track designation and rolling submission for LCZ696 in chronic heart failure, CHMP recommendation …

/by

Sandoz’s Joerg Windisch reelected as chair of Ega’s European biosimilars group

Today, Sandoz announced that the European Generic medicines Agency (EGA) has reelected Dr. Joerg Windisch, Chief Science Officer at Sandoz, as chair of its European Biosimilars Group (EBG).

Read more

/by

Sandoz brings together key French stakeholders to discuss biosimilars

Sandoz, the global leader in biosimilars, recently hosted an event in Paris for key stakeholders to discuss strategic issues impacting biosimilars and help them better understand their vital role in the success of these important therapies in France.

Read more

/by